Towards 50 years of platelet function analyser (PFA) testing

EJ Favaloro, L Pasalic, G Lippi - Clinical Chemistry and Laboratory …, 2023 - degruyter.com
The platelet function analyser (PFA) is a prevalent platelet function screening instrument,
and comes in two models–the original PFA-100 and the contemporary PFA-200. The …

Harmonizing platelet function analyzer testing and reporting in a large laboratory network

EJ Favaloro, S Mohammed, R Vong… - International Journal …, 2022 - Wiley Online Library
Introduction The platelet function analyzer (PFA) is a popular platelet function screening
instrument, highly sensitive to von Willebrand disease (VWD) and to aspirin therapy, with …

[HTML][HTML] Serial Examination of Platelet Function Tests Might Predict Prognosis of Patients with Acute Ischemic Stroke—A Cohort Study

HJ Ho, LC Wu, YW Chen - Diagnostics, 2024 - mdpi.com
Background: This study investigated whether point-of-care platelet function measurements
could predict favorable outcomes in patients with acute ischemic stroke (AIS). Antiplatelet …

Antiplatelet Therapy and Platelet Activity Testing for Neurointerventional Procedures

KA Fukuda, C Beaman, V Szeder - Stroke: Vascular and …, 2025 - ahajournals.org
The management of antiplatelet medications in neurointerventional procedures remains a
subject of considerable variability and debate. This review article explores the diverse …

Comparison of clopidogrel, prasugrel and ticagrelor response of patients by PFA-100-innovance test results

A Sukun, F Tekeli - Indian Journal of Hematology and Blood Transfusion, 2023 - Springer
Devices such as stents and flow diverters require the use of safe and fast antiplatelet
therapy. We aimed to compare the responses to clopidogrel, prasugrel, and ticagrelor by …

Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis

J Shpigelman, A Proshkina, MJ Daly, D Cox - Current Cardiology Reports, 2023 - Springer
Abstract Purpose of Review Dual antiplatelet therapy (DAPT)—aspirin in conjunction with a
P2Y12 inhibitor—is the cornerstone of managing patients with acute coronary syndromes …